Brian Forrest
Family Medicine · Apex, NCNPI 1376540112
Payments from drug & device makers
Across 785 payments — averaging $506.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$370K
- E.r. Squibb & Sons, L.L.C.$18K
- Pfizer$8K
- Regeneron$432
- Novo Nordisk$386
- AbbVie$328
- plus $534 from 12 others
What the payments were for
- Consulting fees$25,5426%
- Speaking & faculty fees$296,45075%
- Travel & lodging$60,45915%
- Food & beverage$15,0814%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 695 | $369,567 |
| E.r. Squibb & Sons, L.L.C. | 18 | $18,035 |
| Pfizer | 17 | $8,250 |
| Regeneron | 1 | $432 |
| Novo Nordisk | 20 | $386 |
| AbbVie | 2 | $328 |
| Lilly USA, LLC | 8 | $167 |
| AstraZeneca | 5 | $76 |
| Merck | 6 | $73 |
| Arbor Pharmaceuticals, Inc. | 3 | $47 |
| Exact Sciences | 2 | $34 |
| Amarin Pharma, Inc. | 2 | $34 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Abiomed | 1 | $19 |
| Boston Scientific | 1 | $18 |
| Medtronic | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$397,532 in reported general payments places this provider in the 95th percentile of 3,444 family medicine providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 41 | $49,199 |
| FarxigaDapagliflozin Propanediol | 17 | $18,639 |
| EliquisApixaban | 22 | $12,817 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $6,932 |
| Nebivolol Hcl | 67 | $3,242 |
| Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide | 53 | $2,294 |
| Celecoxib | 95 | $1,881 |
| Rosuvastatin Calcium | 118 | $1,773 |
| Levothyroxine Sodium | 81 | $1,059 |
| Olmesartan Medoxomil | 64 | $948 |
| Escitalopram Oxalate | 58 | $722 |
| Metformin Hcl | 58 | $643 |
| Pantoprazole Sodium | 65 | $587 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 11 | $525 |
| Dutasteride | 16 | $511 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $386 | $49,19941 claims |
| AstraZenecaFarxiga | $76 | $18,63917 claims |
| PfizerEliquis | $8,250 | $12,81722 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,444 family medicine providers in North Carolina.
Other family medicine in Apex
- Douglas WadesonApex$97K
- Barton WilliamsWilmington$17.3M
- Alexander MurrayGreensboro$13M
- Arin PiramzadianJacksonville$13M
- Jonathan WilsonHickory$12.7M
- George RaadCharlotte$7.7M
- Cecil FarringtonSalisbury$6.4M
- Christian MartinShelby$5.4M
- John EarlHickory$4.7M
- Patrick MorganteHavelock$4.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.